AMEX · MTNB
Healthcare · Biotechnology
$1.51
Down-$0.39 (-20.53%)
Updated Nov 2, 2026, 7:14 AM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · MTNB
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
MTNB closed at $1.51 after 20 trading sessions, down 46.45% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $1.87 | $1.91 | $1.505 | $1.51 | 83K |
| Oct 29, 2026 | $1.88 | $1.90 | $1.88 | $1.90 | 2.69K |
| Oct 28, 2026 | $1.76 | $1.93 | $1.76 | $1.91 | 9.14K |
| Oct 27, 2026 | $1.75 | $1.90 | $1.74 | $1.83 | 27.8K |
| Oct 26, 2026 | $1.59 | $1.75 | $1.58 | $1.66 | 49.73K |
| Oct 23, 2026 | $1.71 | $1.78 | $1.69 | $1.7006 | 11.29K |
| Oct 22, 2026 | $1.53 | $1.80 | $1.52 | $1.71 | 48.43K |
| Oct 21, 2026 | $1.69 | $1.69 | $1.4693 | $1.52 | 19.91K |
| Oct 20, 2026 | $1.66 | $1.72 | $1.51 | $1.70 | 48.56K |
| Oct 19, 2026 | $2.37 | $2.37 | $1.50 | $1.66 | 273.46K |
| Oct 16, 2026 | $2.48 | $2.50 | $2.36 | $2.37 | 27.34K |
| Oct 15, 2026 | $2.44 | $2.54 | $2.42 | $2.42 | 20.95K |
| Oct 14, 2026 | $2.51 | $2.55 | $2.4524 | $2.48 | 19.79K |
| Oct 13, 2026 | $2.72 | $2.72 | $2.46 | $2.50 | 66.37K |
| Oct 12, 2026 | $2.85 | $2.85 | $2.70 | $2.74 | 21.51K |
| Oct 9, 2026 | $2.77 | $2.87 | $2.70 | $2.87 | 40.29K |
| Oct 8, 2026 | $2.73 | $2.8499 | $2.61 | $2.83 | 141.88K |
| Oct 7, 2026 | $2.99 | $2.99 | $2.63 | $2.77 | 172.67K |
| Oct 6, 2026 | $2.76 | $3.15 | $2.64 | $3.01 | 417.68K |
| Oct 5, 2026 | $2.78 | $3.00 | $2.43 | $2.82 | 183.97K |
The latest Smart Investors Daily articles mentioning MTNB.
Company
Market Activity
Research & News
MTNB research
Company profile and research snapshot.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 31, 2024 | Maxim Group | Hold | — |
| Oct 11, 2023 | BTIG | Buy | — |
| Jan 31, 2023 | HC Wainwright & Co. | Buy | — |
| Aug 13, 2020 | Aegis Capital | Buy | — |
| Jan 27, 2020 | Piper Sandler | Overweight | — |
No generated briefing is available yet.
Benzinga · Oct 19, 2026
Gainers Silence Therapeutics (NASDAQ:SLN) stock increased by 125.6% to $19.59 during Monday's regular session. The market value of their outstanding shares is at $581.1 million. SCWorx (NASDAQ:WORX) stock
Benzinga · Sep 16, 2026
On June 23, 2025, at the 2025 annual meeting of stockholders of Matinas BioPharma Holdings, Inc. (the "Company"), the stockholders approved the authorization of the Board of Directors (the "Board"), in
Yahoo · Sep 14, 2026
Agreement establishes GH Power’s first commercial hydrogen offtake and validates hydrogen production from the Company’s proprietary aluminum-water reactor platformToronto, Canada, Sept. 14, 2026 (GLOBE NEWSWIRE) -- GH Power Inc. (“GH Power” or the “Company”) (NYSE American: MTNB), a Canadian clean energy and critical materials technology company, today announced that it has entered into a multi-year hydrogen supply agreement (the “Agreement”) with Change Energy Engineering Inc. on behalf of its
Yahoo · Sep 4, 2026
BEDMINSTER, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on August 31, 2026, it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $2.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MTNB.
